The Supreme Court raised serious concerns about the Pharmacy Council of India's practice of granting yearly approvals to pharmacy colleges instead of stable multi-year recognition. The Court observed this creates regulatory uncertainty that directly harms students who cannot plan their academic futures. The bench called for systemic reform in the Council's approval process, questioning why a statutory regulatory body operates without a consistent long-term framework. The Court flagged that such ad hoc functioning undermines the Council's mandate under the Pharmacy Act, 1948.

The Pharmacy Council of India (PCI) is a statutory body established under the Pharmacy Act, 1948. It regulates pharmacy education and practice across India. The Supreme Court's intervention touches on a recurring tension in Indian regulatory law: the difference between a statutory body acting within its mandate versus acting arbitrarily in ways that harm stakeholders.

The core legal issue here is whether year-to-year approvals constitute an unreasonable regulatory practice. When a statutory regulator creates uncertainty for students — who have enrolled based on an expectation of continuing recognition — it potentially violates legitimate expectation, a principle of administrative law that protects individuals from arbitrary reversal of established practices.

For CLAT PG aspirants, this case connects to PIL maintainability (students or institutions can approach courts when regulatory dysfunction causes harm), administrative law principles (reasonable exercise of statutory power), and the broader question of how courts supervise statutory bodies. The Court's supervisory jurisdiction under Article 136 or writ jurisdiction under Article 32 over statutory regulators is a tested theme.

For UPSC CSE, the structural question is about the PCI's composition, statutory basis, and regulatory architecture — how health profession councils function as part of India's cooperative regulatory framework between Centre and States.